Cargando…

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products

Nonalcoholic steatohepatitis (NASH) is a clinical syndrome with pathological changes that are similar to those of alcoholic hepatitis without a history of excessive alcohol consumption. It is a specific form of nonalcoholic fatty liver disease (NAFLD) that is characterized by hepatocyte inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Gaoxuan, Liu, Ying, Lu, Lu, Zhang, Guangtao, Zhou, Wenjun, Wu, Tao, Wang, Lei, Xu, Hanchen, Ji, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301043/ https://www.ncbi.nlm.nih.gov/pubmed/35873545 http://dx.doi.org/10.3389/fphar.2022.944088

Ejemplares similares

New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer
por: Lu, Lu, et al.
Publicado: (2022)

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
por: Yu, Simiao, et al.
Publicado: (2022)

Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
por: Boslem, Ebru, et al.
Publicado: (2023)

Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer
por: Shao, Gaoxuan, et al.
Publicado: (2022)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

FGF9 Recruits β‐Catenin to Increase Hepatic ECM Synthesis and Promote NASH‐Driven HCC
por: Zhang, Lei, et al.
Publicado: (2023)

Erratum for the Research Article: “Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC”
Publicado: (2023)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Sijunzi decoction granules in the prevention and treatment of recurrence of colorectal adenoma: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
por: Ni, Wenjing, et al.
Publicado: (2023)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
por: Zhang, Guangtao, et al.
Publicado: (2023)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC
por: Ribas, Vicent, et al.
Publicado: (2021)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Molecular Pathogenesis of NASH
por: Caligiuri, Alessandra, et al.
Publicado: (2016)

Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway
por: Desterke, Christophe, et al.
Publicado: (2019)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
por: Gutiérrez-Cuevas, Jorge, et al.
Publicado: (2022)

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?
por: Dong, Jiahuan, et al.
Publicado: (2022)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO
por: Bai, Lu, et al.
Publicado: (2022)

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
por: Motta, Benedetta Maria, et al.
Publicado: (2023)

SLC35B4 Stabilizes c-MYC Protein by O-GlcNAcylation in HCC
por: Jiang, Tao, et al.
Publicado: (2022)

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
por: De Minicis, Samuele, et al.
Publicado: (2014)

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
por: Grohmann, Marcus, et al.
Publicado: (2018)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
por: Ge, Chenxu, et al.
Publicado: (2022)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
por: Wu, Le, et al.
Publicado: (2021)

Natural history of NASH
por: Armandi, Angelo, et al.
Publicado: (2021)

Editorial: Nonalcoholic fatty liver disease: From pathogenesis to phytomedicine based on omics technology
por: Ji, Guang, et al.
Publicado: (2022)

Deciphering the Effective Constituents and Mechanisms of Portulaca oleracea L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology
por: He, Xiaoli, et al.
Publicado: (2022)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

High-fat diet combined with dextran sulfate sodium failed to induce a more serious NASH phenotype than high-fat diet alone
por: Zhou, Yan, et al.
Publicado: (2022)

Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics
por: Velázquez-Díaz, Pamela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bp1vrkcekt7v4ajsbdr154hmrj